Biomarin Pharmaceutical Inc. - Registered Shares (BMRN) Company Profile & Statistics

Biomarin Pharmaceutical Inc. - Registered Shares
BMRN
(Nasdaq - US)
Open
63.18
-0.24 (-0.38%)
in:usd•As of: Nov 18, 2024 10:48 UTC -5
Open
63.24
High
63.53
Low
62.88

About Biomarin Pharmaceutical Inc. - Registered Shares

CEO

Alexander Hardy

Headquarters

770 lindaro street

san rafael, ca 94901, united states

Auditor

KPMG LLP

Employees

3,401

Share Holders

Website

www.bmrn.com

Industry

biotechnology

Sector

health technology

Company Overview

BioMarin Pharmaceutical Inc. focuses on the development and commercialization of treatments for serious life-threatening medical conditions, mostly for children. The company's portfolio comprises seven marketed products namely, Aldurazyme, Naglazyme, Kuvan a rare genetic enzyme deficiency disorder), Vimizim , Brineura, Palynziq and Voxzogo. BioMarin has a collaboration agreement with Sanofi's subsidiary Genzyme for Aldurazyme. Genzyme is BioMarin's sole customer for Aldurazyme and is responsible for marketing and selling Aldurazyme to third parties.?The newest drug in BioMarin's portfolio, Voxzogo for treating achondroplasia, the most common form of dwarfism. BioMarin's biologics license application (BLA) for Roctavian/valoctocogene roxaparvovec (valrox), a gene therapy for severe hemophilia A, was given a complete response letter (CRL) by the FDA.

Biomarin Pharmaceutical Inc. - Registered Shares Statistics

Valuation Measures

Market Capitalization ²	12.04B
Enterprise Value	11.96B
Enterprise Value/EBITDA (ttm)	28.96
Price to Earnings Ratio (ttm)	28.06
Price to Book (mrq)	2.23
Price to Sales (ttm)	4.39
Price to Cash (ytd)	35.45

Profitability

Gross Margin (ttm)	79.61%
Operating Margin (ttm)	16.06%
Profit Margin (ttm)	11.52%
Return on Equity (ttm)	8.53%
Return on Invested Capital (ttm)	5.52%
Return on Assets (ttm)	6.40%

Income Statement

Revenue (ttm)	2.75B
Revenue Per Share (ttm)	14.44
Gross Profit (ttm)	2.19B
EBITDA (ttm)³	413.02M
Net Income Avi to Common (ttm)	322.29M
Diluted EPS (ttm)	1.67

Share Statistics

Beta (5Y Monthly)	0.31
52-Week Change	-27.82%
S&P500 52-Week Change	29.56%
S&P500 Member	No
Stock Optionable	Yes
Total Shares Outstanding ¹	190.58M
Dividend Yield	0.00%
Float ⁴	187.06M
% Held by Insiders	1.85%
% Held by Institutions	98.71%

Balance Sheet

Total Cash (mrq)	930.44M
Total Cash Per Share (mrq)	4.88
Total Debt (mrq)	594.63M
Total Debt/Equity (mrq)	10.98%
Current Ratio (mrq)	4.27%
Quick Ratio (mrq)	2.62%
Book Value Per Share (mrq)	28.41

Cash Flow

Operating Cash Flow Per Share (ytd)	1.96
Free Cash Flow (ytd)	331.32M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. Stock price provided by Xignite. All numbers are rounded to the closest decimal.

¹ Total Shares outstanding is taken from the most recently filed quarterly or annual report.

² Market Cap is calculated using total shares outstanding and the most recent share price.

³ EBITDA is calculated using methodology that may differ from that used by a company in its reporting.

⁴ The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.

Biomarin Pharmaceutical Inc. - Registered Shares

Trade With A Regulated Broker